CN Patent

CN119156202A — 包含阿替卡普兰的组合物

Assigned to Janssen Pharmaceuticals Inc · Expires 2024-12-17 · 1y expired

What this patent protects

本公开涉及包含阿替卡普兰的组合物，包括呈片剂形式的口服组合物，以及使用该组合物的方法。

USPTO Abstract

本公开涉及包含阿替卡普兰的组合物，包括呈片剂形式的口服组合物，以及使用该组合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN119156202A
Jurisdiction
CN
Classification
—
Expires
2024-12-17
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.